In re Application of:

Chien et al.

PATENT
Attorney Docket No.: ST-UCSD3230-1

Application No.: 10/705,791 Filed: November 10, 2003

Page 2

Amendments to the Claims:

Please amend claim 18 and add new claims 36-38, as indicated below in the listing of claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-17. (Cancelled).

18. (Currently Amended) A method for treating a loss of cardiac muscle contractility associated with heart failure comprising:

delivering an expression construct to myocytes cardiomyocytes in a mammalian host suffering from heart failure, wherein the expression construct provides an expressible polynucleotide encoding a phospholamban molecule having a point mutation consisting of S16E, wherein expression of a therapeutic level of the polynucleotide stimulates improved cardiac muscle contractility.

- 19. (Previously Presented) The method according to claim 18, wherein the expression construct is a viral vector.
 - 20-23. (Cancelled).
- 24. (Previously Presented) The method according to claim 19, wherein the viral vector is a DNA vector.
 - 25. (Withdrawn). The method as in claim 18, wherein the coding sequence is RNA.
 - 26. (Withdrawn) A method for treatment of heart failure comprising:

In re Application of:

Chien et al.

Application No.: 10/705,791

Filed: November 10, 2003

Page 3

PATENT
Attorney Docket No.: ST-UCSD3230-1

delivery of a DNA construct to heart comprising a coding sequence for an antisense phospholamaban RNA wherein transcription of the coding sequence is controlled by a promoter functional in heart and the antisense phospholamban RNA increases cardiac contractility or cardiac relaxation.

- 27. (Withdrawn) The method as in claim 26, wherein the coding sequence is delivered using a viral vector.
- 28. (Withdrawn) The method as in claim 26, wherein the coding sequence is delivered by injection into the heart.
- 29. (Withdrawn) The method as in claim 26, wherein the coding sequence is delivered by direct injection into the heart.
- 30. (Withdrawn) The method as in claim 26, wherein the coding sequence is delivered by transcoronary injection into the heart.
 - 31. (Withdrawn) The method as in claim 26, wherein the coding sequence is DNA.
 - 32-35. (Cancelled)
- 36. (New) A method for treating a loss of cardiac muscle contractility associated with heart failure comprising:

delivering, via intracoronary administration, an expression construct to cardiomyocytes in a mammalian host suffering from heart failure, wherein the expression construct provides an expressible polynucleotide encoding a phospholamban molecule having a point mutation consisting of S16E, wherein expression of a therapeutic level of the polynucleotide stimulates improved cardiac muscle contractility.

In re Application of:

Chien et al.

Application No.: 10/705,791

Filed: November 10, 2003

Page 4

37. (New) The method according to claim 36, wherein the expression construct is a viral vector.

Attorney Docket No.: ST-UCSD3230-1

38. (New) The method according to claim 37, wherein the viral vector is a DNA vector.